Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | CES2 | O00748 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188862 | 1.00 | NPSR1 (0.44) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL215091 | 1.00 | NPSR1 (0.44) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL15492593 | 0.88 | NPSR1 (0.33) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL24811635 | 0.88 | NPSR1 (0.33) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL5074733 | 0.88 | NPSR1 (0.43) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL15281988 | 0.86 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL19222 | 0.86 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1828802 | 0.86 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1828800 | 0.86 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL19223 | 0.86 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957124-A | 3- (trifluoromethyl) -pyrazole-4-carboxylic ester derivative and preparation method and application thereof | 浙江工业大学 | 2022-08-30 | — | — | CN | claimed |
| US-20260132158-A1 | PHENYL OXY AMIDE KINASE INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INST (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4673150-A2 | COMPOSITIONS AND METHODS FOR TREATING MALT1 ASSOCIATED DISEASES | Rarefied Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4648851-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | Astrazeneca AB (SE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | RAREFIED BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4617269-A1 | NOVEL COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2025-09-17 | — | — | EP | disclosed |
| EP-4499611-A1 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-6743798-B1 | CARDIOVASCULAR DISORDERS; VASORELAXATION, INHIBITION OF PLATELET AGGREGATION, DECREASE IN BLOOD PRESSURE; STIMULATION OF SOLUBLE GUANYLATE CYCLASE AND AN INTRACELLULAR CGMP INCREASE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003002062-A2 | BIS-ARYL THIAZOLE DERIVATIVES | TULARIK INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5852028-A | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5811428-A | ADMINISTERING FOR THE TREATMENT AND PREVENTION OF IMMUNOINFLAMMATORY AND AUTOIMMUNE DISEASES | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| EP-0850228-A1 | PYRIMIDINE CARBOXAMIDES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1997009315-A1 | PYRIMIDINE CARBOXAMIDES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | MALT1, SQSTM1, PPP1R10 | NPSR1 4749/4885GLO1 2055/4885ALDH1A1 3447/4885 |
| US-20260132158-A1 | PHENYL OXY AMIDE KINASE INHIBITORS | RAF1, CNKSR1, PHKG1 | NPSR1 1523/4885GLO1 2943/4885ALDH1A1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.